This is a working overview of actin-binding fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-06. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
==== List of P-CABs in the markets (First year of approval for clinical use) ==== Revaprazan (2006) Vonoprazan (2014) Tegoprazan (2018) Fexuprazan (2021) Keverprazan (2023/China) Zastaprazan (2024/South Korea)
== Software and tools == Software tools for bioinformatics include simple command-line tools, more complex graphical programs, and standalone web-services. They are made by bioinformatics companies or by public institutions.
== After Liberation == Smolková-Keulemansová suffered from dysentery, jaundice, typhus and tuberculosis after liberation. She could not give an address to anyone she knew in Prague, so the International Red Cross did not allow her to return to her country of origin. To receive medical treatment, she was selected to go to Sweden for a six-month recovery stay with 6,000 other prisoners.
In a famous game in 2004, with 35 seconds remaining and the scores deadlocked at 131 points apiece, Essendon legend James Hird swooped on a loose ball in the right forward pocket and snapped a match-winning goal with his 15th possession for the quarter, famously hugging an Essendon supporter in the crowd in a moment of jubilation after being fined $20,000 earlier in the week for criticising umpire Scott McLaren. Full-forward Matthew Lloyd also kicked eight goals during the game to net three Brownlow votes. Despite Hird's incredible individual effort, and to the consternation of fans and the audience of the 2004 Brownlow medal count, he did not receive any Brownlow Medal votes from the umpires for his 34 disposals and clutch goals, which some have speculated was in retribution for his tirade against umpire McLaren.
=== Government and NGO reports === National Drug Threat Assessment 2009 from the United States Department of Justice War On Drugs: Legislation in the 108th Congress and Related Developments, a 2003 report from the Congressional Research Service via the State Department website The Report of the Canadian Government Commission of Inquiry into the Non-Medical Use of Drugs – 1972 Drug Enforcement Administration (2017), Drugs of abuse: A DEA resource guide (PDF) (2017 ed.), Washington, D.C.: Author, archived from the original (PDF) on December 3, 2016, retrieved January 23, 2018 Revealing the missing link to Climate Justice: Drug Policy, a 2023 report from the International Coalition on Drug Policy Reform and Environmental Justice
Sources: en.wikipedia.org
=== Adoption by BIPM until 2026 === The IUPAC 1961 definition of the unified atomic mass unit, with that name and symbol "u", was adopted by the International Bureau for Weights and Measures (BIPM) in 1971 as a non-SI unit accepted for use with the SI. From 2026, the BIPM no longer describes it, or other units, as accepted for use with SI; it is listed among a group of "Internationally recognised units that are not decimal multiples or submultiples of SI units".
=== Systems Pharmacology === Systems Pharmacology models integrate pharmacokinetics, pharmacodynamics, and systems biology to provide a comprehensive understanding of drug effects. By considering the intricate interplay between drugs, biological systems, and disease pathways, these models contribute to a holistic approach to drug development and personalized medicine.
Obesity is distributed unevenly across racial groups in the United States. Many racial minority populations disproportionately reside in low-income neighborhoods that can lack resources such as adequate healthcare, safe recreational areas, and grocery stores offering affordable, nutritious food options such as fresh fruits and vegetables. Furthermore, minority households can be more prone to obesity because of cultural food preferences and family norms. The higher prevalence of obesity among Black women compared to other demographics has been attributed to influence from cultural beauty ideals that tolerate or favor fuller body shapes. Hispanics have a high genetic susceptibility to obesity, as their Native American ancestors had adapted to a low-calorie diet, which predisposes Hispanics to obesity in the modern world, where high calorie foods are abundant.
Communicates with sensory neurons. Mesencephalon Also known as the midbrain, this region of the brainstem is involved in motor control, vision, hearing, and alertness. Metabotropic receptor A type of neurotransmitter receptor that activates a second messenger system via G-proteins, resulting in slower but longer-lasting cellular effects. Microelectrode A very fine electrode used to record the electrical activity of individual neurons. Microglia The resident immune cells of the central nervous system, responsible for clearing debris, responding to injury, and regulating inflammation. Middle ear The air-filled space containing the auditory ossicles (malleus, incus, stapes) that transmit sound from the outer ear to the inner ear. Midbrain A portion of the brainstem that includes structures such as the tectum and tegmentum. It plays roles in vision, hearing, motor control, and arousal. Mismatch negativity (MMN) An event-related potential detected via EEG that reflects automatic brain response to deviations in auditory stimuli. Used in studies of perception and schizophrenia. Mitochondria Organelles responsible for energy production in cells. In neurons, they play critical roles in metabolism, calcium regulation, and apoptosis. Molecular layer The outermost layer of the cerebellar cortex and cerebral cortex (in some regions), containing relatively few neurons and mostly dendrites, axons, and synapses. Monoamine oxidase (MAO) An enzyme that breaks down monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine. Targeted by some antidepressants.
Sources: en.wikipedia.org
Hunkapiller's idea would require competing against his own customers, to all of whom Applied Biosystems sold its sequencing machines and their chemical reagents. However, he calculated that it would also mean doubling the market for that equipment. Hunkapiller brought in Dr. J. Craig Venter to direct the project. Tony White, president of the Perkin-Elmer Corporation backed Hunkapiller on the venture. They organized the new company to accomplish the task. In May 1998, Celera Genomics was formed, to rapidly accelerate the human DNA sequencing process. Dr. Venter boldly declared to the media that he would complete the genome decoding by 2001. That bold announcement prompted the academic consortium to accelerate their own deadline by a couple years, to 2003. Also in 1998, PE Biosystems partnered with Hitachi, Ltd. to develop electrophoresis-based genetic analysis systems, which resulted in their chief new genomics instrument, the ABI PRISM 3700 DNA Analyzer, which advanced the Human Genome sequencing project by nearly five years ahead of schedule. The partnerships sold hundreds of the 3700 analyzers to Celera, and also to others worldwide. The new machine cost US$300,000 each, but was a major leap beyond its predecessor, the 377, and was fully automated, allowing genetic decoding to run around the clock with little supervision. According to Venter, the machine was so revolutionary that it could decode in a single day the same amount of genetic material that most DNA labs could produce in a year.
Fish protein powder (FPP) describes a food grade powder product designated primarily for human consumption applications. It differs significantly from fish meal products which are designated for animal feed applications. Fish protein powders have various sanitary processing, purity and functional characteristics which establish them as human food ingredients. Production plants registered for the USA market are located in Peru and France.
=== Bibliography === Algar, Hamid (1989). "BEKTĀŠĪYA". Encyclopaedia Iranica. Vol. IV. pp. 118–122. Doja, Albert. 2006. "A political history of Bektashism from Ottoman Anatolia to Contemporary Turkey." Journal of Church and State 48 (2): 421–450. doi=10.1093/jcs/48.2.423. Doja, Albert. 2006. "A political history of Bektashism in Albania." Politics, Religion & Ideology 7 (1): 83–107. doi=10.1080/14690760500477919. Elsie, Robert (2001). A Dictionary of Albanian Religion, Mythology and Folk Culture. New York: New York University Press. ISBN 978-1-85065-570-1. Nicolle, David; UK (1995). The Janissaries (5th). Osprey Publishing. ISBN 1-85532-413-X. Muhammed Seyfeddin Ibn Zulfikari Derviş Ali; Bektaşi İkrar Ayini, Kalan Publishing, Translated from Ottoman Turkish by Mahir Ünsal Eriş, Ankara, 2007 Turkish Saggau, Emil BH. "Marginalised Islam: Christianity's role in the Sufi order of Bektashism." In Exploring the Multitude of Muslims in Europe, pp. 183–197. Brill, 2018. Soileau, Mark (2014). "Conforming Haji Bektash: A Saint and His Followers between Orthopraxy and Heteropraxy." Die Welt des Islams 54, pp. 423-459
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.